Coppell Advisory Solutions’s Ascendis Pharma A/S ASND Stock Holding History

Coppell Advisory Solutions’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-141	Closed	-$19.2K	–	433
2024 Q4	$19.2K	Hold	141	–	–	﹤0.01%	901
2024 Q3	$20.4K	Hold	141	–	–	﹤0.01%	872
2024 Q2	$20.4K	Buy	+141	New	+$19.2K	﹤0.01%	780
2023 Q4	$13.5K	Buy	141 +65	+86%	+$6.48K	﹤0.01%	858
2023 Q3	$136	Sell	76 -441	-85%	-$41.3K	﹤0.01%	1136
2023 Q2	$45.2K	Buy	+517	New	+$45K	0.01%	410
2023 Q1	–	Sell	-50	Closed	-$90	–	258
2022 Q4	$90	Buy	+50	New	+$5.8K	﹤0.01%	1148

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coppell Advisory Solutions's ASND Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Ascendis Pharma A/S (ASND) in Q1 2025, closing a stake of 141 shares — an estimated $19.2K sold.

Coppell Advisory Solutions first reported a position in ASND in Q4 2022 and held it in 7 quarters. The position peaked at $45.2K in Q2 2023. 244 funds tracked by Wall St. Rank hold ASND as of Q1 2025.

Coppell Advisory Solutions reported no remaining Ascendis Pharma A/S position as of Q1 2025 after selling out during the quarter.
Coppell Advisory Solutions sold 141 Ascendis Pharma A/S shares in Q1 2025, an estimated $19.2K.
Coppell Advisory Solutions first reported a position in Ascendis Pharma A/S in Q4 2022 and held it in 7 quarters.
Coppell Advisory Solutions's Ascendis Pharma A/S position peaked at $45.2K in Q2 2023.
244 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.